ADVM · As filed with the SEC
Adverum Biotechnologies income statement, by fiscal year
The statement as Adverum Biotechnologies presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS · USD thousands, except per-share amounts; shares in thousands
| USD thousands, except per-share amounts; shares in thousands | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 |
|---|---|---|
| License revenue | 1,000 | 3,600 |
| Operating expenses: | ||
| Research and development | 77,041 | 77,486 |
| General and administrative | 63,118 | 55,056 |
| Total operating expenses | 140,159 | 132,542 |
| Operating loss | (139,159) | (128,942) |
| Other income, net | 8,232 | 5,748 |
| Net loss before income taxes | (130,927) | (123,194) |
| Income tax benefit | 0 | 1,078 |
| Net loss | (130,927) | (122,116) |
| Other comprehensive gain (loss): | ||
| Net unrealized gain on marketable securities | 105 | 1,057 |
| Foreign currency translation adjustment | (39) | 1 |
| Comprehensive loss | (130,861) | (121,058) |
| Net loss per share - basic (in USD per share) | (6.62) | (12.11) |
| Net loss per share - diluted (in USD per share) | (6.62) | (12.11) |
| Weighted-average common shares outstanding - basic (in shares) | 19,782 | 10,082 |
| Weighted-average common shares outstanding - diluted (in shares) | 19,782 | 10,082 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.